227 Statutory Reports 24 - 109 Financial Statements 110 - 263 Corporate Overview 01 - 23 (` cr) No. Particulars As at March 31, 2021 Unbillied Not due Less than 1 year 1-2 years 2-3 years More than 3 years Total 1. MSME - 23.17 0.37 - - - 23.54 2. Others 55.82 386.61 96.40 0.48 0.27 0.01 539.59 55.82 409.78 96.77 0.48 0.27 0.01 563.13 (` cr) Note 21 Contract liabilities As at March 31, 2022 As at March 31, 2021 a) Advances received from customers 33.82 24.43 33.82 24.43 (` cr) Note 22 Revenue from operations 2021-22 2020-21 Sale of products 4,825.13 3,633.15 Sale of services1 190.74 45.28 Scrap sales 15.42 7.99 Commission received 0.02 0.01 Processing charges 8.35 9.54 Revenue from contracts with customers 5,039.66 3,695.97 Export incentives 41.23 35.50 5,080.89 3,731.47 1Includes ` 188.52 cr (2020-21: ` 43.53 cr) on account of freight and insurance in sale of goods on CIF, which are identified as separate performance obligation under Ind AS 115. Disaggregation of revenue from contracts with customers (` cr) Particulars 2021-22 2020-21 Sale of goods | services Life Science Chemicals 1,449.36 1,204.36 Domestic 695.16 642.93 Export 754.20 561.43 Performance and Other Chemicals 3,733.69 2,598.38 Domestic 2,018.16 1,455.47 Export 1,715.53 1,142.91 Others 69.97 48.48 5,253.02 3,851.22 Inter-segment revenue 213.36 155.25 5,039.66 3,695.97 Note 20 Trade payables (continued)
RkJQdWJsaXNoZXIy MjA2MDI2